pd-l1/ctla4 bsab
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 26, 2019 (NCT04324307)
Timeline
Indications
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
- Cytotoxic T-lymphocyte protein 4INHIBITOR
CTLA4 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06404736 | Phase 2 | May 7, 2024 | Fudan University |
| NCT04324307 | Phase 1/Phase 2 (Phase 2) | Nov 26, 2019 | Changhai Hospital |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Changhai Hospital | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1